These 100% medical-grade silicone fine-line patches can now be worn all night. Pespire innovated on their reusable silicone neck and chest anti-wrinkle patches by upgrading the adhesive to improve all-night comfort. Their 2-pack of chest or neck patches are now available on Amazon with discount pricing for a limited time! Customers usually apply these pads […]
Progressive Multifocal Leukoencephalopathy Market (Albany, USA) DelveInsight’s “Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Progressive Multifocal Leukoencephalopathy, historical and forecasted epidemiology as well as the Progressive Multifocal Leukoencephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Progressive Multifocal […]
Deep Partial-thickness Thermal Burns Market DelveInsight’s “Deep Partial-Thickness Thermal Burns Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Deep Partial-Thickness Thermal Burns, historical and forecasted epidemiology as well as the Deep Partial-Thickness Thermal Burns market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. […]
DelveInsight’s, Non-Small-Cell Lung cancer Pipeline Insight 2023” report provides comprehensive insights about 135+ companies and 150+ pipeline drugs in Non-Small-Cell Lung cancer pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including Non-Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the Non-Small Cell Lung Cancer therapeutics assessment […]
DelveInsight’s, “Metastatic Triple-Negative Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Metastatic Triple-Negative Breast Cancer (mTNBC) pipeline landscape. It covers the Metastatic Triple-Negative Breast Cancer pipeline drug profiles, including Metastatic Triple-Negative Breast Cancer clinical trials and nonclinical stage products. It also covers the Metastatic Triple-Negative Breast […]
DelveInsight’s, “Brain Metastasis from Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Brain Metastasis from the Breast Cancer pipeline landscape. It covers the Brain Metastasis from Breast Cancer pipeline drug profiles, including Brain Metastasis from Breast Cancer clinical trials and nonclinical stage products. It also covers […]
DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insights, 2023” report provides comprehensive insights about 90+ companies and 110+ pipeline drugs in the metastatic prostate cancer pipeline landscape. It covers the Metastatic Prostate Cancer pipeline drug profiles, including Metastatic Prostate Cancer clinical trials and nonclinical stage products. It also covers the Metastatic Prostate Cancer therapeutics assessment by product […]
DelveInsight’s, “Prostate Cancer Pipeline Insight 2023” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including Prostate Cancer clinical trials and nonclinical stage products. It also covers the Prostate Cancer pipeline therapeutics assessment by product type, stage, route of […]
DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including Metastatic Castration-Resistant Prostate Cancer clinical trials and nonclinical stage products. It also covers the Metastatic Castration-Resistant Prostate […]
Acurx Pharmaceuticals (NasdaqCM: ACXP) announced completing a stock purchase agreement with a single institutional investor in May 2023, offering a mix of shares and warrants to provide ACXP with $4.0 million before fees and offering expenses at $3 per share. Ironically, shares traded lower on the deal’s announcement. But that’s not necessarily bad news. The […]
